Zymeworks to Present at Upcoming Investor Conferences

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in three upcoming virtual investor conferences.

• Wells Fargo’s 2020 Healthcare Conference is scheduled for September 9-10, 2020. Zymeworks is presenting on Wednesday, September 9, 2020 at 11:20 a.m. ET.
• Citi’s 15th Annual BioPharma Conference is scheduled for September 9-10, 2020.
• H.C. Wainwright’s 22nd Annual Global Investment Conference is scheduled for September 14-16, 2020. Zymeworks is presenting on Tuesday, September 15, 2020 at 2:30 p.m. ET.

Interested parties can access a live webcast of the presentations via a link from Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations, which will also host recorded replays available afterwards.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody currently in a registration-enabling clinical trial for refractory HER2+ biliary tract cancer as well as several Phase 2 clinical trials for HER2+ gastroesophageal and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit www.zymeworks.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200903005113/en/

Investor Inquiries:  
Ryan Dercho, Ph.D.  
(604) 678-1388  
[email protected]  
 
Tiffany Tolmie  
(604) 678-1388  
[email protected]  
 
Media Inquiries:  
Kavita Shah, Ph.D. 
(604) 678-1388  
[email protected]

Source: Zymeworks Inc.

You May Also Be Interested In

• Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometri
• Faraday Future Announces Completion of FF EAI Robotics Ecosystem's (FFR) Acquisition of Faraday Future's Robotics Business and Establishment of a Nasdaq-Listed Humanoid and Bionic Robotics Platform
• FF EAI Robotics Ecosystem Completed its Acquisition of the Robotics Business of Faraday Future, Establish Nasdaq-Listed Humanoid and Bionic Robotics Platform